The available data revealed a result that there were no enhanced PCa risks for population-based (OR = 1.0675, 95% CI = 0.9221–1.2359, P = 0.3817, I2 = 62.58%), hospital-based (OR = 0.9667, 95% CI = 0.7548–1.238, P = 0.7883, I2 = 66.95%) or BPH-based (OR = 1.2012, 95% CI = 0.7568–1.9065, P = 0.4367, I2 = 81.31%) controls with the GSTP1 A131G polymorphism. Here, GSTP1 is linked to benign prostatic hyperplasia.